Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

M A Stone, U Payne, C Pacheco-Tena, R D Inman

Research output: Contribution to journalArticle

  • 35 Citations

Abstract

Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p
LanguageEnglish
Pages84-87
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume63
Issue number1
DOIs
StatusPublished - 2004

Fingerprint

Ankylosing Spondylitis
Tumor Necrosis Factor-alpha
Cytokines
Transforming Growth Factor beta
Interleukin-10
Biomarkers
Therapeutics
Infliximab

Cite this

Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. / Stone, M A; Payne, U; Pacheco-Tena, C; Inman, R D.

In: Annals of the Rheumatic Diseases, Vol. 63, No. 1, 2004, p. 84-87.

Research output: Contribution to journalArticle

Stone, M A ; Payne, U ; Pacheco-Tena, C ; Inman, R D. / Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. In: Annals of the Rheumatic Diseases. 2004 ; Vol. 63, No. 1. pp. 84-87
@article{6f98ddca047246a783c2bd8b35e1ace4,
title = "Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis",
abstract = "Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p",
author = "Stone, {M A} and U Payne and C Pacheco-Tena and Inman, {R D}",
note = "ID number: ISI:000187808300018",
year = "2004",
doi = "10.1136/ard.2003.006916",
language = "English",
volume = "63",
pages = "84--87",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis

AU - Stone,M A

AU - Payne,U

AU - Pacheco-Tena,C

AU - Inman,R D

N1 - ID number: ISI:000187808300018

PY - 2004

Y1 - 2004

N2 - Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p

AB - Objective: To identify clinical and immunological markers of response to treatment with infliximab in ankylosing spondylitis (AS). Methods: Baseline and sequential cytokine levels (IL1, TNFalpha, IFNgamma, TGFbeta and IL10) were examined after 52 weeks of infliximab treatment 5 mg/kg in 22 patients. Results: At week 52, 18 patients were responders and four non-responders according to ASAS group criteria. Clinical measures of disease activity between the two groups at baseline were similar, apart from a trend towards longer disease duration in non-responders (p = 0.08). Baseline CRP and TNFalpha levels were higher in responders than non-responders (p

U2 - 10.1136/ard.2003.006916

DO - 10.1136/ard.2003.006916

M3 - Article

VL - 63

SP - 84

EP - 87

JO - Annals of the Rheumatic Diseases

T2 - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 1

ER -